Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2468 participants.

Also called NCT05577988

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose other
Phase
Phase 3
Enrolled
  • 2,468 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05577988
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05577988. Randomized; single masking; primary purpose other. Start 2024-06-18 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
Acronym
ADEN
Intervention (Other)
single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Fonds de Dotation ACTION (class: other)

Record details

Record id
cardio:ct-nct05577988
Content hash
2ea4b8e92de9cf1cd4c34310ddb7ddcaae102195971aa8af04e0fa03eb1da0a5